Loading data for DSGN — first visit, this takes a few seconds.

알림

Design Therapeutics Inc. (DSGN)

NasdaqGS: DSGN · 실시간 가격 · USD

14.99

-0.57 (-3.66%)

종가 기준: Aug 26, 2026, 8:00 PM

15.62

+0.17%

애프터마켓: 6:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-3.66% (1D)

데이터 없음

매수호가	11.17
시가총액	975.65M
매출 (ttm)	n/a
순이익 (ttm)	-70.8M
	1.64
	-1.18
	n/a
	-9.79
P/B (ttm)	4.83
P/S (ttm)	n/a
실적 발표일	Nov 5, 2026

매도호가	19.2
거래량	552,135
평균 거래량 (20일)	738,727
시가	15.66
전일 종가	15.56
일중 범위	14.98 - 15.83
52주 범위	4.92 - 17.25
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

DSGN 소개

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedrei...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Mar 29, 2021

직원 수 55

상장 거래소 NasdaqGS

티커 DSGN

웹사이트 https://www.designtx.com

전체 기업 정보

재무 실적

2025년 Design Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -69.79M로, 40.74% 증가했습니다.

재무제표

어닝 서프라이즈

Design Therapeutics가 Aug 3, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.32 예상치 상회 0.02, 및 5.88% 전년 대비 성장.

다음 실적 발표

Design Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2개월 전 · Zacks

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.

3개월 전 · Investor's Business Daily

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost it all.

3개월 전 · InvestorsHub

Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)

Stock Surges Following Positive Clinical UpdateShares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the company released favorable four-week data from its RESTORE-FA clinical trial ...

3개월 전 · Insider Monkey

Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec”

Design Therapeutics, Inc. (NASDAQ:DSGN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. A caller asked for Cramer’s thoughts ...

3개월 전 · Zacks

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 페이지 중 1

Design Therapeutics Inc. (DSGN)